Workers Compensation
Medicines started for an acute injury quietly become permanent as a claim prolongs, and the prescribing cascade begins. Some new symptoms are not a new condition. They are the medication list talking.
Why do acute treatment plans outlive the acute phase?
A treatment plan written in the first fortnight of a claim answers the questions of the first fortnight: control pain, protect sleep, and keep the person functioning while tissue heals. The medicines chosen for that job are acute tools with short intended lifespans. The Faculty of Pain Medicine (ANZCA) frames opioids for acute injury in days, with most acute episodes needing less than a week of therapy. RACGP guidance positions benzodiazepines as a short course of one to four weeks. The z drug sleep medicines carry a maximum of around four weeks in their own product information. Pregabalin is indicated for neuropathic pain, not general injury pain.
Claims do not always follow that script. Australian research in CNS Drugs (2025) found around one in five new back and neck claims is dispensed an opioid within the first 90 days, and workers still off work at three months face roughly eight times the risk of persistent opioid use. Earlier Australian work found about a third of injured workers who start opioids progress to long-term use. The acute treatment plan that authorised a medicine in week one rarely names the date the medicine should stop, so renewal becomes the default. Nobody decides the plan will run for a year. It simply is not un-decided.
What is a prescribing cascade?
The term was coined by Rochon and Gurwitz in 1995 and revisited in The Lancet in 2017. A prescribing cascade begins when an adverse drug reaction is misinterpreted as a new medical condition, and a second medicine is prescribed to treat it. The second medicine brings its own side effects, which can trigger a third prescription, and the list compounds. The textbook examples are a calcium channel blocker causing ankle swelling that earns a diuretic, or an anti-inflammatory raising blood pressure that earns an antihypertensive. On an injury claim, the cascade usually runs through the pain and psychotropic medicines, one defensible step at a time.
| Step | Added to the file | The stated reason | What it actually layers on |
|---|---|---|---|
| 1 | Short-acting opioid | Acute injury pain | Appropriate for days, but tolerance builds as use continues |
| 2 | Slow-release opioid | Pain persisting, "better baseline cover" | Round-the-clock opioid load, sedation, hormone suppression begins |
| 3 | Pregabalin | Possible neuropathic component, often never formally diagnosed | Sedation, dizziness, cognitive blunting, recognised risk of suicidal ideation |
| 4 | Antidepressant | The person reports feeling depressed | Mood and agitation can worsen in the early weeks before any benefit arrives |
| 5 | Benzodiazepine | Anxiety or distress while the antidepressant settles | Dependence risk within weeks, stacked on two other sedating medicines |
Notice what happened. The depression being treated at step four is consistent with the sedation and cognitive decline produced at steps two and three, and the crisis being managed at step five is consistent with pregabalin's own product warnings and the recognised early worsening on a newly started antidepressant. Victorian ambulance data published in the MJA (2019) found pregabalin-related attendances rose more than tenfold between 2012 and 2017, with around 40 per cent involving a suicide attempt. Yet at every step, the prescriber treated what was in front of them.
If the person comes out the other side, the bill keeps running. Long-term opioid therapy suppresses sex hormones, with a 2020 review finding around 63 per cent of men on long-term opioids have suppressed testosterone. The combined sedative load disrupts sleep architecture and REM sleep, so the person sleeps more and restores less. Poor sleep, inactivity and weight gain then pull cardiovascular and metabolic risk in behind them. Five medicines, one original injury, and not one confirmed new pathology required at any point.
How does a side effect become a new diagnosis on a claim?
Claims are structured in a way that helps the misreading along. A new symptom generates a new referral, and the new specialist sees the symptom in their own domain rather than the dispensing history behind it. Sedation, poor concentration and flattened mood emerging months into a claim can be certified as a secondary psychological condition when they are consistent with the combined load of an opioid, a benzodiazepine and pregabalin. Once the new diagnosis is on the certificate it attracts its own treatment pathway, its own costs and often its own prescriber, and the medicine that started the chain is now one step further from scrutiny.
Multiple prescribers make this worse. When a GP, a pain specialist and a psychiatrist each manage their own corner of the file, no single clinician owns the whole list, and medication side effects fall into the gaps between them. The question that breaks the chain is simple and cheap: could an existing medicine be doing this? It just has to be asked before the referral, not after.
What does unmanaged polypharmacy cost?
The Pharmaceutical Society of Australia's Medicine Safety: Take Care report (2019) puts the national picture plainly: 250,000 hospital admissions every year are medication related, with another 400,000 emergency department presentations, at a cost of around 1.4 billion dollars annually. At least half of that harm is preventable. Population research in the Medical Journal of Australia (2019) found almost one million older Australians take five or more medicines every day, which is where uninterrupted cascades eventually lead.
At the sharpest end, the Penington Institute's Annual Overdose Report (2025) shows the combination that builds most easily on injury claims, an opioid plus a benzodiazepine, is the most common poly-drug pairing behind opioid overdose deaths in Australia. Among poly-substance deaths involving pharmaceutical opioids, 70.3 per cent also involved benzodiazepines and 45.4 per cent involved antidepressants. Polypharmacy in injury claims rarely announces itself as a crisis. It accrues one defensible prescription at a time.
What should the plan review look like as a condition prolongs?
The fix is not a better initial plan. It is treating the treatment plan as a dated document that expires, the way a certificate of capacity does. As a condition moves from acute to persistent, the plan should be actively re-made, not rolled over.
- Put review dates on medicines, not just on the claim: around one week for opioids in acute injury, about four weeks for benzodiazepines and z drugs, then every renewal after that.
- Reconcile the full list at each review point, across every prescriber and including over-the-counter medicines, against the original injury.
- Ask the medicine question first: before any new symptom becomes a new referral, check whether it appeared after a medication start or dose change.
- Make deprescribing part of the plan in writing, as a planned taper with the prescriber, so stopping is as deliberate as starting.
The one-line habit: every time a new symptom appears on a long-running claim, the first note on the file should answer "which current medicine could cause this?" before it answers "which specialist should see this?"
When should an injury manager request an independent medication review?
An independent medication review earns its keep at specific trigger points: a medicine has run past its guideline window and is being renewed unchanged; a new diagnosis has appeared after a medication start or dose change; three or more centrally acting medicines sit on the same file; more than one prescriber is writing scripts; or return to work has stalled and sedation is a plausible reason. The reviewing pharmacist maps what was started when and why, identifies which symptoms line up with which medicines, and gives the treating GP specific, actionable recommendations, including taper plans where deprescribing is warranted. Because the reviewer does not dispense or prescribe, the advice carries no financial interest in any medicine staying on the list.
Key Takeaways
- Medicines chosen for the acute phase of an injury have guideline lifespans measured in days to weeks, and a plan that is rolled over rather than reviewed lets them run for years.
- A prescribing cascade starts when an adverse drug reaction is misread as a new condition and a new medicine is prescribed to treat it.
- Some secondary diagnoses on long-running claims are medication side effects wearing a new label, and the medication timeline is the way to tell the difference.
- Medication-related problems cause 250,000 Australian hospital admissions a year, and at least half are preventable.
- Treatment plans should expire like certificates do, with review dates attached to each medicine and a written deprescribing pathway.
- An independent medication review is most valuable when a new diagnosis follows a medication change, or when multiple prescribers share one growing list.
Frequently Asked Questions
What is a prescribing cascade?
A prescribing cascade happens when a side effect of one medicine is misread as a new medical condition, and a second medicine is prescribed to treat it. Each addition brings its own side effects and interactions, so the list can keep growing while the original problem is never fixed.
How do I know whether a new diagnosis is actually a medication side effect?
Line the symptom up against the medication timeline. If it first appeared after a medicine was started or a dose was changed, treat the medicine as a suspect before accepting a new condition. An independent pharmacist can map that timeline from the dispensing history and advise the treating GP.
When should an acute treatment plan be reviewed?
At the guideline windows for the medicines on it: around one week for opioids in acute injury, and about four weeks for benzodiazepines and z drugs. After that, review whenever a medicine is renewed unchanged, a new prescriber joins the file, or a new symptom appears.
Does fixing polypharmacy mean stopping medicines abruptly?
No. Deprescribing is a planned, gradual taper led by the treating prescriber, usually one medicine at a time with monitoring. Abruptly stopping opioids or benzodiazepines is unsafe and is not what a medication review recommends.
Primary source: Pharmaceutical Society of Australia, Medicine Safety: Take Care report, 2019.
